• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Dermata Therapeutics Shares Are Trading Higher By Over 100%; Here Are 21 Stocks Moving Premarket

    12/30/22 6:26:40 AM ET
    $ARBK
    $BXRX
    $DRMA
    $EVAX
    Finance: Consumer Services
    Finance
    Misc Health and Biotechnology Services
    Health Care
    Get the next $ARBK alert in real time by email

    Gainers

    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) shares rose 105% to $0.41 in pre-market trading after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the contemplated public offering.
    • Evaxion Biotech A/S (NASDAQ:EVAX) rose 34.4% to $2.38 in pre-market trading. Evaxion Biotech said on Dec 22, the FDA notified the company that it had reviewed the company's IND for Phase 2b clinical trial of EVX-01 in combination with Keytruda.
    • Sesen Bio, Inc. (NASDAQ:SESN) shares rose 30.4% to $0.6590 in pre-market trading after the company and Carisma Therapeutics announced an increased special dividend of $70 million, or $0.34 per share, in connection with the pending merger.
    • Tuesday Morning Corporation (NASDAQ:TUEM) rose 22.8% to $0.84 in pre-market trading after gaining around 16% on Thursday. Tuesday Morning recently announced it will voluntarily delist from the Nasdaq Capital Market.
    • Landos Biopharma, Inc. (NASDAQ:LABP) rose 17.7% to $0.60 in pre-market trading after gaining 12% on Thursday.
    • Palisade Bio, Inc. (NASDAQ:PALI) rose 17.1% to $3.77 in pre-market trading after jumping 78% on Thursday. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction in intra-abdominal adhesions in subjects following elective bowel resection.
    • Lightning eMotors, Inc. (NYSE:ZEV) shares rose 16.3% to $0.38 in pre-market trading. Lightning eMotors recently received continued listing standards notice from NYSE.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) rose 15% to $0.5997 in pre-market trading.
    • Getaround, Inc. (NYSE:GETR) rose 14% to $0.5702 in pre-market trading after dropping around 8% on Thursday. Piper Sandler initiated coverage on Getaround with an Overweight rating and announced a price target of $1.5.
    • ASAP, Inc. (NASDAQ:ASAP) rose 12.3% to $0.38 in pre-market trading.
    • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) rose 11.1% to $1.60 in pre-market trading after surging 21% on Thursday.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) rose 11% to $0.0810 in pre-market trading after dropping 11% on Thursday. Panbela Therapeutics recently filed prospectus for public offering for up to 4.7 million shares of common stock.
    • Shaw Communications Inc. (NYSE:SJR) rose 10.3% to $29.11 in pre-market trading. Canada's competition tribunal approved Rogers Communications’ $14.8 billion offer for Shaw Communications.
    • National CineMedia, Inc. (NASDAQ:NCMI) rose 9.3% to $0.26 in pre-market trading.

     

    Losers

    • Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares fell 32.8% to $7.20 in pre-market trading. Hoth Therapeutics shares jumped around 144% on Thursday after the FDA accepted the IND application for HT-001.
    • Argo Blockchain plc (NASDAQ:ARBK) fell 18.3% to $0.7387 in pre-market trading after gaining 23% on Thursday. Argo Blockchain recently entered into definitive agreements with Galaxy Digital Holdings, under which an Argo subsidiary will sell its Helios facility in Dickens County, Texas for $65 million.
    • Pineapple Energy Inc (NASDAQ:PEGY) fell 7% to $1.88 in pre-market trading after jumping 22% on Thursday. EF Hutton recently initiated coverage on Pineapple Energy with a Buy rating and announced a price target of $5.5.
    • Baudax Bio, Inc. (NASDAQ:BXRX) fell 6.4% to $3.36 in pre-market trading after jumping around 56% on Thursday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) shares fell 6.4% to $0.18 in pre-market trading after declining around 20% on Thursday. Rubius Therapeutics, last month, initiated a process to explore a range of strategic alternatives and plans to engage an investment bank to act as a strategic advisor for this process.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) fell 6.3% to $0.0780 in pre-market trading after gaining 5% on Thursday. Esports Entertainment Group recently announced registered direct offering, private placement.
    • Quotient Limited (NASDAQ:QTNT) fell 5.5% to $0.3497 in pre-market trading after jumping 54% on Thursday.

    Read This Next: Investor Fear Eases After Nasdaq Rises More Than 2%

    Get the next $ARBK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARBK
    $BXRX
    $DRMA
    $EVAX

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    National CineMedia Inc.
    $NCMI
    10/31/2025$7.00 → $6.50Outperform
    Barrington Research
    National CineMedia Inc.
    $NCMI
    5/16/2025$6.00Buy → Neutral
    B. Riley Securities
    National CineMedia Inc.
    $NCMI
    3/14/2025$7.50Neutral → Outperform
    Wedbush
    Argo Blockchain plc
    $ARBK
    1/8/2025Underperform
    Keefe Bruyette
    More analyst ratings

    $ARBK
    $BXRX
    $DRMA
    $EVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Evaxion A/S

    3 - Evaxion A/S (0001828253) (Reporting)

    3/18/26 9:13:18 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Evaxion A/S

    3 - Evaxion A/S (0001828253) (Reporting)

    3/18/26 9:12:04 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Evaxion A/S

    3 - Evaxion A/S (0001828253) (Reporting)

    3/18/26 9:11:27 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARBK
    $BXRX
    $DRMA
    $EVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARBK
    $BXRX
    $DRMA
    $EVAX
    SEC Filings

    View All

    SEC Form 10-K filed by Palisade Bio Inc.

    10-K - PALISADE BIO, INC. (0001357459) (Filer)

    3/20/26 4:22:38 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/19/26 9:10:04 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    3/19/26 9:00:05 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARBK
    $BXRX
    $DRMA
    $EVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    China SXT Pharmaceuticals, Inc. Announces Share Re-classification

    TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that upon the market opening on March 24, 2026, the Company's Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol "SXTC". On July 28, 2025, the Company held a special meeting of shareholders (the "Meeting"). At the Meeting

    3/23/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Notice to convene Evaxion's Annual General Meeting

    COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET. The meeting will be held at the company's offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. The agenda and proposals can be found on Evaxion's website, along with other materials: www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/ Contact information Evaxion A/SMads KronborgVice President, Investor Relations & Communication+45 53 54 82 96 [email protected] About Evaxion Evaxion is a pione

    3/19/26 9:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026

    ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company

    3/19/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ARBK
    $BXRX
    $DRMA
    $EVAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARBK
    $BXRX
    $DRMA
    $EVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARBK
    $BXRX
    $DRMA
    $EVAX
    Financials

    Live finance-specific insights

    View All

    Evaxion plans to file 2025 annual report later today

    COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will slightly delay the filing and publication of its 2025 annual report, planned before opening of Nasdaq CM today, due to unforeseen technical issues with external vendors.   The report has been finalized as planned and will be filed and published as soon as possible. The technical issues relate to regulatory filing demands and have nothing to do with the report itself.  As a consequence of the technical delay, the conference call and webcast planned for today will be moved to tomorrow: Friday March 6 at 8.30 E

    3/5/26 8:02:13 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Evaxion to announce business update and full year 2025 financial results on March 5, 2026

    COPENHAGEN, Denmark, March 2, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its full year 2025 financial results on Thursday March 5, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces

    3/2/26 8:00:00 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    National CineMedia, Inc. Reports Results for Fiscal Fourth Quarter and Full Year 2025

    Fourth quarter operating income increases year-over-year and fourth quarter adjusted OIBDA exceeds guidance Fourth quarter revenue growth of 8% outpaced attendance as NCM attracted greater advertiser demand National CineMedia, Inc. (NASDAQ:NCMI) (the "Company" or "NCM"), the managing member of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising platform in the U.S., announced today its consolidated results for the fiscal fourth quarter and year ended January 1, 2026. "NCM expanded fourth quarter revenue by 8% year-over-year, demonstrating the returns from our continued investment in our platform over the course of the year," said Tom Lesinski, Chief Execu

    2/26/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    $ARBK
    $BXRX
    $DRMA
    $EVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by National CineMedia Inc.

    SC 13D/A - National CineMedia, Inc. (0001377630) (Subject)

    11/20/24 9:34:56 PM ET
    $NCMI
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care